Skip to main content
Neuland Laboratories Limited. logo

Neuland Laboratories Limited. — Investor Relations & Filings

Ticker · NEULANDLAB ISIN · INE794A01010 LEI · 335800AVHZURTYQ17N08 BSE.NS Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2023-05-11 Annual Report
Country IN India
Listing BSE.NS NEULANDLAB

About Neuland Laboratories Limited.

https://www.neulandlabs.com

Neuland Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and provides comprehensive Custom Manufacturing Solutions (CMS). The company focuses on complex chemistry and high-quality standards, operating state-of-the-art manufacturing facilities that comply with international regulatory requirements, including those of the USFDA and EDQM. Its product portfolio spans diverse therapeutic areas such as cardiovascular, central nervous system, anti-infectives, and antiasthmatics. Neuland supports pharmaceutical companies globally through the entire lifecycle of a drug, from early-stage clinical development to commercial-scale production. By leveraging advanced technical expertise and a robust quality management system, the organization delivers reliable chemical synthesis and process optimization services to both innovator and generic drug manufacturers.

Recent filings

Filing Released Lang Actions
Dividend
Annual Report Classification · 100% confidence The document is a detailed communication from Neuland Laboratories Limited to stock exchanges regarding the outcome of a Board Meeting held on May 11, 2023. It includes approval of audited standalone and consolidated financial results for the fiscal year ended March 31, 2023, along with the statement of assets and liabilities. The document contains the auditor's report with an unmodified opinion, detailed financial statements, and notes. It also mentions the recommendation of a final dividend for the year 2022-23. The presence of comprehensive audited financial results, auditor's opinion, and detailed financial data for the full fiscal year indicates this is the official Annual Report or equivalent annual financial results filing. The document is lengthy (15,000 characters) and contains substantive financial data, not merely an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K equivalent).
2023-05-11 English
Financial Result Updates
Annual Report Classification · 100% confidence The document is a detailed communication from Neuland Laboratories Limited to stock exchanges regarding the outcome of a Board Meeting held on May 11, 2023. It includes approval of audited standalone and consolidated financial results for the fiscal year ended March 31, 2023, along with the statement of assets and liabilities. The document contains the auditor's report with an unmodified opinion, detailed financial statements, and notes. It also mentions the recommendation of a final dividend for the fiscal year 2022-23. The presence of comprehensive audited financial results, auditor's opinion, and detailed financial data for the full fiscal year indicates this is an Annual Report type filing. It is not merely an announcement or a brief summary but contains substantive financial data and audit details. Therefore, the appropriate classification is Annual Report (10-K).
2023-05-11 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) regarding the loss of share certificates by a shareholder and the request for issuance of a 'Letter of Confirmation' in lieu of physical share certificates. It references Regulation 39(3) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, which pertains to share certificate loss and related disclosures. The document is short (1354 characters) and serves as an official notification to the exchanges rather than a financial report or detailed filing. It does not contain financial data, management discussion, voting results, or any other report content. This type of notification fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-05-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Earnings Release Classification · 95% confidence The document is a letter addressed to stock exchanges announcing the schedule for the Q4 and full year FY 2023 earnings call of Neuland Laboratories Limited. It references the upcoming earnings announcement date (May 11, 2023) and provides details for the earnings call, including registration information. The document does not contain actual financial results or detailed financial statements but serves as a notice for the earnings release and call. The document length is short (2783 characters) and primarily serves as an announcement rather than the earnings release itself or the call transcript. Therefore, the appropriate classification is Earnings Release (ER) as it is an initial announcement of quarterly/periodical financial results and the earnings call notice. FY 2023
2023-05-04 English
Credit Rating
Capital/Financing Update Classification · 95% confidence The document is a short communication addressed to stock exchanges regarding an upgrade in the company's credit rating by CRISIL. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an update on credit rating changes, which is a capital/financing related announcement. The document length is only 1083 characters, indicating it is a brief notice rather than a detailed report. Therefore, it fits best under Capital/Financing Update (CAP).
2023-04-25 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, concerning the encumbrance of shares by the promoter group during the financial year 2022-23. It is addressed to stock exchanges and relates to compliance with takeover regulations. The content is a formal declaration about share encumbrance status, which aligns with notifications about major shareholding or changes in share ownership levels. It is not a full report, financial statement, or management discussion, nor is it an announcement of voting results or a proxy statement. Therefore, the document fits best under the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding declaration, supporting this classification with high confidence.
2023-04-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.